Boston Scientific Corp. (NYSE:BSX) has entered into a definitive agreement to acquire Valencia Technologies Corp., a private medical technology firm, in a strategic move to dominate the high-growth market for overactive bladder treatments.
The deal adds the FDA-approved eCoin® System to Boston Scientific’s urology and pelvic health lineup.
The eCoin is a leadless, coin-sized neurostimulator implanted near the ankle that automatically delivers electrical pulses to the tibial nerve, helping to regulate bladder function.
In pivotal clinical trials, the device demonstrated a 68% responder rate, defined as patients achieving at least a 50% reduction in urge urinary incontinence (UUI) episodes.
Unlike traditional sacral neuromodulation, the eCoin is implanted via a minimally invasive procedure under local anesthesia, offering a "set-and-forget" alternative for the estimated 30 million U.S. adults suffering from overactive bladder.
The acquisition is expected to close in the first half of 2026, subject to customary closing conditions.
Boston Scientific noted that the transaction is expected to have an immaterial impact on adjusted earnings per share in 2026, though it will be more dilutive on a GAAP basis due to acquisition-related charges and amortization.